How India Exports Tiotropium to the World

In the United States, tiotropium bromide is approved for the maintenance treatment of COPD. The reference listed drug (RLD), Spiriva HandiHaler (NDA 021395), was approved by the FDA on January 30, 2004. Subsequently, generic versions have entered the market. For instance, Lupin Pharmaceuticals received FDA approval for its Abbreviated New Drug Application (ANDA 211287) for Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, on October 30, 2025. This approval underscores the stringent regulatory pathway involving bioequivalence studies and adherence to Current Good Manufacturing Practices (cGMP). The presence of 99 active Indian exporters highlights the competitive landscape and the importance of maintaining compliance with FDA regulations to ensure market access.

In the European Union, tiotropium bromide is authorized for COPD treatment. The European Medicines Agency (EMA) granted marketing authorization for Spiriva HandiHaler, with the marketing authorization issued on September 30, 2002. The UK, post-Brexit, continues to recognize EMA approvals; however, the Medicines and Healthcare products Regulatory Agency (MHRA) now oversees national authorizations. Manufacturers exporting to these markets must comply with EU Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety.

Tiotropium bromide is included in the 21st edition of the WHO Model List of Essential Medicines, reflecting its critical role in managing COPD. While not listed under the WHO Prequalification Programme, tiotropium must meet international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure global quality compliance.

In India, tiotropium bromide is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for tiotropium, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and international standards.

The primary patents for Spiriva HandiHaler have expired, facilitating the entry of generic versions into the market. This has intensified competition among manufacturers, including Indian exporters, necessitating adherence to regulatory standards to maintain market share.

In October 2025, the FDA approved Lupin Pharmaceuticals' ANDA for Tiotropium Bromide Inhalation Powder, marking a significant milestone for Indian manufacturers in the US market. In November 2025, the EMA updated the product information for Ultibro Breezhaler, a combination therapy including indacaterol and glycopyrronium, indicating ongoing regulatory activities in the COPD treatment landscape. (ema.europa.eu) In December 2025, the WHO released the 22nd edition of the Model List of Essential Medicines, reaffirming the inclusion of tiotropium bromide, underscoring its global therapeutic importance.

These developments highlight the dynamic regulatory environment and the necessity for Indian exporters to stay abreast of international standards and approvals to sustain and expand their market presence.

Tiotropium bromide, the active pharmaceutical ingredient (API) in Tiotropium formulations, is predominantly manufactured in India. However, the production of this API is heavily reliant on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a critical supplier for the pharmaceutical industry. This dependency poses significant risks, as any disruption in the supply of these materials can halt API production, leading to shortages of the final pharmaceutical product.

Recent geopolitical tensions have exacerbated these risks. In March 2026, military conflicts in the Middle East led to the closure of the Strait of Hormuz, a vital maritime chokepoint. This disruption has caused significant delays and increased costs in the transportation of goods, including pharmaceutical raw materials. Such events highlight the vulnerability of supply chains that are heavily dependent on specific regions for critical raw materials.

The export data for Tiotropium from India reveals a high supplier concentration, with the top five exporters accounting for 98.3% of the total export value. LUPIN LIMITED alone holds an 80.6% share, amounting to $54.8 million USD. This level of concentration indicates a significant single-source risk, as any operational or regulatory issues affecting these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of APIs and reducing reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics, marking a step towards decreasing import dependence. However, the effectiveness of this initiative in diversifying the supplier base for Tiotropium remains to be seen.

The closure of the Strait of Hormuz in March 2026 due to military conflicts has had a profound impact on global supply chains. This strategic chokepoint is crucial for the transportation of oil and other goods, including pharmaceutical raw materials. The disruption has led to increased shipping costs and extended transit times, affecting the timely delivery of essential components for drug manufacturing.

Additionally, the ongoing tensions in the Red Sea and the Strait of Hormuz have further complicated shipping routes, leading to rerouting and additional delays. These geopolitical issues underscore the fragility of supply chains that rely on specific maritime routes and highlight the need for strategic planning to mitigate such risks.

• Diversify Supplier Base: Encourage the development of alternative suppliers for both APIs and KSMs to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical raw materials and APIs to decrease reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans and maintain strategic stockpiles to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains.

• Engage in Strategic Partnerships: Collaborate with international partners to secure diversified and reliable sources for raw materials and APIs.

RISK_LEVEL: HIGH